Bank of America Merrill Lynch 20230214_HORIZON THERAPEUTICS PLC_38.5 (b)_IE (0269Q)
15 Febbraio 2023 - 11:54AM
UK Regulatory
TIDMTTM TIDMHZNP
RNS Number : 0269Q
Bank of America Merrill Lynch
15 February 2023
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT,
1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED
INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader BofA Securities, Inc.
Company dealt in HORIZON THERAPEUTICS PLC
-------------------------
Class of relevant security to which the Common - IE00BQPVQZ61
dealings being disclosed relate(Note 1)
-------------------------
Date of dealing 14/02/2023
-------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing)
in the class of relevant security
dealt in (Note 2)
Class of relevant security: Common IE00BQPVQZ61
Long Short
----------------- ------------------
Number % Number %
-------- ------- -------- --------
(1) Relevant securities 357,435 0.156% 76,044 0.033 %
-------- ------- -------- --------
(2) Derivatives (other than options): 307,381 0.134% 314,265 0.137%
-------- ------- -------- --------
(3) Options and agreements to purchase/sell: 0 0% 38,600 0.017%
-------- ------- -------- --------
Total 664,816 0.291% 428,909 0.187%
-------- ------- -------- --------
(b) Interests and short positions in relevant securities
of the company, other than the
class dealt in (Note 2)
Class of relevant security:
Long Short
------------ ------------
Number % Number %
------- --- ------- ---
(1) Relevant securities 0 0% 0 0%
------- --- ------- ---
(2) Derivatives (other than options): 0 0% 0 0%
------- --- ------- ---
(3) Options and agreements to purchase/sell: 0 0% 0 0%
------- --- ------- ---
Total 0 0% 0 0%
------- --- ------- ---
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 700 109.6 USD
------------------------------ ------------------------
Purchase 2,500 109.5 USD
------------------------------ ------------------------
Purchase 900 109.585 USD
------------------------------ ------------------------
Purchase 800 109.595 USD
------------------------------ ------------------------
Purchase 100 109.583 USD
------------------------------ ------------------------
Purchase 1,200 109.445 USD
------------------------------ ------------------------
Purchase 100 109.44 USD
------------------------------ ------------------------
Purchase 500 109.43 USD
------------------------------ ------------------------
Purchase 400 109.45 USD
------------------------------ ------------------------
Purchase 100 109.433 USD
------------------------------ ------------------------
Purchase 100 109.435 USD
------------------------------ ------------------------
Purchase 100 109.443 USD
------------------------------ ------------------------
Purchase 2,500 109.48 USD
------------------------------ ------------------------
Purchase 10,151 109.55 USD
------------------------------ ------------------------
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 2,500 109.645 USD
------------------------------ ------------------------
Sale 744 109.69 USD
------------------------------ ------------------------
Sale 300 109.7 USD
------------------------------ ------------------------
Sale 4,700 109.71 USD
------------------------------ ------------------------
Sale 10,100 109.55 USD
------------------------------ ------------------------
Sale 1,000 109.705 USD
------------------------------ ------------------------
Sale 200 109.695 USD
------------------------------ ------------------------
Sale 300 109.715 USD
------------------------------ ------------------------
Sale 256 109.725 USD
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
(c) Options transactions in respect of existing relevant
securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry date Option money paid/ received
name, selling, securities price e.g. American, per unit (Note 4)
e.g. call purchasing, to which European
option varying the option etc
etc. relates (Note
7)
N/A N/A N/A N/A N/A N/A N/A
------------- --------------- --------- ---------------- ------------ ------------------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 4)
N/A N/A N/A
---------------------- --------------------
(d) Other dealings (including transactions in respect
of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7) (if applicable) (Note 4)
Collateral Delivery Collateral Delivery of 66,900 shares N/A
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 15/02/2023
Contact name Frank Lui
-----------------------
Telephone number +44207 996 6418
-----------------------
Name of offeree/offeror with which connected AMGEN INC
-----------------------
Nature of connection (Note 9) Advisor to - AMGEN INC
-----------------------
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEFLFEIFIIELIV
(END) Dow Jones Newswires
February 15, 2023 05:54 ET (10:54 GMT)
Grafico Azioni Amgen (LSE:0R0T)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Amgen (LSE:0R0T)
Storico
Da Giu 2023 a Giu 2024
